Eli Lilly’s shares soared by more than 12% on Thursday following breakthrough results from a pivotal Phase 3 study of its oral diabetes medication Orforglipron. The experimental pill demonstrated impressive efficacy in adults with Type 2 diabetes, not only significantly reducing blood sugar levels but also producing substantial weight loss. Patients lost an average of 7.3 kilograms (approximately 8% of body weight) over 40 weeks, potentially outperforming Novo Nordisk’s injectable Ozempic, which typically achieves about 6% weight reduction in comparable studies. The medication’s safety profile aligned with other GLP-1 class drugs, with common side effects including nausea, diarrhea, and vomiting, though importantly, no concerning liver signals were detected – a significant advantage over Pfizer’s recently discontinued competing product.
Market Impact and Future Outlook
Sollten Anleger sofort verkaufen? Oder lohnt sich doch der Einstieg bei Eli Lilly?
As the first small-molecule GLP-1 candidate to successfully complete Phase 3 trials, Orforglipron represents a potential game-changer
Dieser Beitrag wurde original veröffentlicht auf: link zum Beitrag
